Building on this body of data, we hypothesized that inhibiting mTORC1 and 2 (therefore decreasing the levels of p-AKT and p-S6K) in combination with chemotherapy may improve the outcomes of patients with ovarian cancer. The gene discussed is RPS6KB1; the disease is ovarian cancer.